LON:GNS Genus (GNS) Share Price, News & Analysis GBX 1,996 -49.00 (-2.40%) As of 10:23 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesBuy This Stock About Genus Stock (LON:GNS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Genus alerts:Sign Up Key Stats Today's Range 1,980▼ 2,08550-Day Range 1,585.52▼ 2,129.3752-Week Range 1,424▼ 2,160Volume70,510 shsAverage Volume245,740 shsMarket Capitalization£1.31 billionP/E Ratio165.45Dividend Yield1.60%Price TargetGBX 2,150Consensus RatingBuy Company OverviewGenus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.Read More… Genus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreGNS MarketRank™: Genus scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingGenus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenus has only been the subject of 1 research reports in the past 90 days.Read more about Genus' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Genus is 166.40, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Genus is 166.40, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.42.Price to Earnings Growth RatioGenus has a PEG Ratio of 2.87. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGenus has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for GNS. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldGenus pays a meaningful dividend of 1.69%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthGenus does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Genus is 265.25%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about Genus' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for GNS. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Genus this week, compared to 1 article on an average week.Search Interest14 people have searched for GNS on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.75% of the stock of Genus is held by insiders.Percentage Held by Institutions77.79% of the stock of Genus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Genus' insider trading history. Receive GNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genus and its competitors with MarketBeat's FREE daily newsletter. Email Address GNS Stock News Headlines1 stock from the FTSE 250 that could be set for a big turnaround5 hours ago | msn.comGenus Stock Price HistoryJune 10, 2025 | investing.com"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.July 1 at 2:00 AM | Crypto 101 Media (Ad)Institutional investors in Genus plc (LON:GNS) lost 3.3% last week but have reaped the benefits of longer-term growthMay 26, 2025 | finance.yahoo.comUK shares advance as investors react to wave of corporate earningsApril 30, 2025 | msn.comGenus rockets 27% in the FTSE 250! Should I buy this UK stock?April 30, 2025 | msn.comFour Brands Making Their Debut at Watches and Wonders 2025April 2, 2025 | msn.comKepler Capital Keeps Their Buy Rating on Genus plc (GNS)March 5, 2025 | markets.businessinsider.comSee More Headlines GNS Stock Analysis - Frequently Asked Questions How have GNS shares performed this year? Genus' stock was trading at GBX 1,550 at the beginning of 2025. Since then, GNS shares have increased by 29.5% and is now trading at GBX 2,007.50. View the best growth stocks for 2025 here. How were Genus' earnings last quarter? Genus plc (LON:GNS) announced its earnings results on Thursday, February, 27th. The company reported $39.80 EPS for the quarter. Genus had a trailing twelve-month return on equity of 1.41% and a net margin of 1.18%. Read the conference call transcript. How do I buy shares of Genus? Shares of GNS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Genus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genus investors own include Meta Platforms (META), Lloyds Banking Group (LLOY), Rolls-Royce Holdings plc (RR.L), AstraZeneca (AZN), Barclays (BARC), BP (BP) and Clinigen Group (CLIN). Company Calendar Last Earnings2/27/2025Today7/01/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryPersonal Services Current SymbolLON:GNS CIKN/A Webwww.genusplc.com Phone+44-1256-347100FaxN/AEmployees480Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 2,150 High Stock Price TargetGBX 2,150 Low Stock Price TargetGBX 2,150 Potential Upside/Downside+7.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 12.06 Trailing P/E Ratio166.27 Forward P/E Ratio28.27 P/E Growth2.87Net Income£7.87 million Net Margins1.18% Pretax MarginN/A Return on Equity1.41% Return on Assets3.31% Debt Debt-to-Equity Ratio53.12 Current Ratio1.80 Quick Ratio1.08 Sales & Book Value Annual Sales£666.67 million Price / Sales1.97 Cash FlowGBX 39.67 per share Price / Cash Flow50.56 Book ValueGBX 827.95 per share Price / Book2.42Miscellaneous Outstanding Shares65,483,478Free FloatN/AMarket Cap£1.31 billion OptionableNot Optionable Beta0.37 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (LON:GNS) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genus plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Genus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.